Pharmaceutical Registration in Costa Rica: DRPIS, Regístrelo and ICH Recognition

Costa Rica is the most institutionally developed market in Central America, and it behaves accordingly — more process, more transparency, and a regulator you can actually plan against.

Two features make it distinctive for an exporter. Registration is filed through a national online platform rather than over a counter, which removes a great deal of the ambiguity that slows filings elsewhere in the region. And Costa Rica has a formal mechanism for recognising registrations granted by ICH member authorities, which is the most explicit reliance route available anywhere in Central America.

The commercial picture is dominated by one buyer to an extent that has no real parallel in the region, and understanding that is more important than any regulatory detail on this page.

Medicines are regulated by the Dirección de Regulación de Productos de Interés Sanitario (DRPIS) within the Ministry of Health (Ministerio de Salud).

Submissions are made through Regístrelo, Costa Rica's online platform for sanitary registration of regulated products. Filing is electronic, with defined document requirements and a trackable process.

This matters more than it sounds. In markets where submissions are physical and status is opaque, a great deal of project time is spent simply finding out where things stand. A structured electronic platform removes much of that, and it also means incomplete submissions tend to be identified early rather than after a long silence.

Costa Rica applies RTCA requirements as a member of the Central American harmonised framework.

A locally established entity is required to hold the registration and be answerable to the Ministry of Health.

The familiar trade-off applies. What is different in Costa Rica is that the professionalised regulatory services sector is better developed than in most of the region, so using an independent regulatory representative — holding the registration while distributors are appointed commercially — is a genuinely practical option rather than a theoretical one.

Given that Costa Rica is often used as a bridgehead for the wider Central American bloc, keeping the registration independent of any single distributor has more strategic value here than the domestic sales figures alone would justify.

Costa Rica applies the RTCA requirement set, submitted through Regístrelo. Expect:

• Certificate of Pharmaceutical Product (CPP/CoPP), legalised for use in Costa Rica.
• GMP certificate and manufacturing licence.
• Technical monograph and finished product specifications — organoleptic, physical, chemical, biological and microbiological — conforming to RTCA standards for human pharmaceutical products.
• Validated analytical methods in accordance with RTCA standards, with the corresponding validation study reports.
• Stability study reports in accordance with current Central American Technical Regulations.
• Bioequivalence studies where required for the product.
• Labelling for primary and secondary packaging plus the insert, as originals or drafts, conforming to RTCA labelling standards.
• Legalised power of attorney for the local holder.

The requirement set is more explicitly specified than in most regional markets, which is helpful — but it also means partial submissions are identified quickly. Assemble fully before filing rather than expecting to supplement.

Costa Rica has the most explicit reliance mechanism in Central America, and it is underused.

Decree No. 43590-S establishes requirements and procedure for the homologation or recognition of sanitary registration of medicines granted by regulatory authorities that are members of the International Council for Harmonisation (ICH).

The practical implication is direct. If your product holds a registration granted by an ICH member authority, there is a defined route to recognition rather than full assessment — a formal, published mechanism rather than discretionary reliance. For companies with EU, US, Japanese or other ICH-member approvals, this should be the first question asked on a Costa Rican project, not a fallback considered after a standard filing has stalled.

Alongside it sit two further levers. RTCA harmonisation means the dossier serves the wider bloc, and Costa Rica operates mutual recognition arrangements within that framework. And the general PAHO reliance picture applies — the eight Regional Reference Regulatory Authorities are ANMAT, ANVISA, Health Canada, ISP, INVIMA, CECMED, US FDA and COFEPRIS.

Confirm current scope, conditions and applicability to your product with the DRPIS. Recognition mechanisms have defined limits and are not automatic.

The electronic platform makes the process more predictable than most regional markets, but the fundamental driver is unchanged: elapsed time depends on how complete and correct the submission is.

Costa Rica's structured requirements cut both ways. A well-prepared dossier moves efficiently. A partial one is identified quickly and clearly, which is better than silence but still costs a cycle.

Within the Central American framework, some analytical standards and samples may be requested after registration under post-authorisation analysis arrangements — confirm how that applies to your product.

Registrations run for a fixed term and require renewal. Track alongside your other RTCA-bloc renewals.

Foreign documents require authentication before Costa Rican authorities will accept them.

Costa Rica is a party to the Hague Apostille Convention, as is India, so apostille rather than full consular legalisation will generally apply to public documents. Confirm the current position before arranging consular appointments.

The standing issues:

• CoPP validity expiring before the filing completes.
• Commercial documents requiring notarisation to qualify for apostille.
• Certified Spanish translation meeting local formal requirements.
• Exact name consistency across every document — worth extra attention where submission is electronic and documents are checked systematically.

Exceptional import mechanisms cover the standard situations: no registered equivalent, shortage or supply interruption, public health need, orphan and rare disease products, and clinical trial material under its own authorisation route.

Costa Rica's version has a particular character. Because the health system is well organised and largely centralised, unmet need tends to be identified formally and pursued through institutional channels rather than left to individual improvisation. Requests are generally well documented and clinically substantiated, and the process is correspondingly more procedural than in less structured markets.

For a supplier that is good news — the requests you receive are usually genuine and well specified. It also means the documentation expectations are higher, and an incomplete response is less likely to be waved through than somewhere with more discretion in the system.

Standard conditions apply: authorisation per consignment against a justification, applied for by the importing institution or licensed importer, and not a route around registration for continuous supply.

Confirm current conditions with the DRPIS.

An unregistered medicine may be imported for an individually identified patient, on a treating physician's responsibility, where no suitable registered alternative exists.

Typically required: prescription naming the patient, clinical justification, authority authorisation before the goods move, quantity limited to the treatment course, batch CoA and provenance.

Compassionate use and expanded access for clinical-stage products sit under their own framework.

Costa Rica is one of the more straightforward Central American markets for this work. Infrastructure is good, the medical system is well organised, San José has solid international air connections, and cold chain handling is more reliable than in most neighbouring countries. Where a regional named patient consignment is difficult to route directly, Costa Rica is sometimes the more sensible entry point.

The country also has a substantial medical tourism sector, which generates requests for therapies familiar in North America but not registered locally — usually from well-informed physicians who know precisely what they are asking for.

Further reading: our global guide to named patient import programmes, our named patient supply service, and our cold chain logistics page.

This is the section that matters most on this page.

Costa Rican public healthcare is dominated by the CCSS — Caja Costarricense de Seguro Social, which operates the public health system and covers the great majority of the population. As a pharmaceutical purchaser the CCSS is one of the largest single buyers in Central America, and its procurement decisions effectively define the accessible public market.

The strategic consequence is unlike anywhere else in the region. In most markets you build a portfolio and pursue several institutional customers. In Costa Rica, for the public channel, there is substantially one customer — and the practical questions are whether your product is on its list, how its purchasing cycles run, and what its technical requirements are. A registration without a route into CCSS procurement may produce very little volume regardless of how good the product is.

A valid registration is generally required to participate, so registration comes first — but registration alone is not a commercial strategy here.

The private sector and medical tourism channels operate separately and reward different things: specific brands, faster decisions, less price sensitivity. Worth planning for deliberately rather than treating as residual.

The PAHO Strategic Fund is available as a parallel route, with eligibility resting on WHO Prequalification at tender opening or approval by regulatory authorities of regional reference. Confirm current criteria with PAHO.

Our government and institutional tender supply page covers the technical file that decides bids before price is opened.

Costa Rica offers a route most of its neighbours do not, and it belongs at the top of your list.

If you hold an ICH-member registration, start with Decree 43590-S. Companies routinely assemble a full RTCA dossier for Costa Rica without ever establishing whether the recognition route was open to them — which is an expensive way to avoid one conversation.

• Never investigating ICH recognition under Decree 43590-S despite holding a qualifying registration.
• Partial submissions through Regístrelo. The platform surfaces gaps quickly; assemble fully before filing.
• Analytical method validation reports missing or inadequate — explicitly required and a common gap.
• Labelling not conforming to RTCA standards for primary, secondary and insert.
• Registering without a CCSS strategy, then finding the public volume unreachable.
• Expired or mismatched certificates.

If you hold a registration from an ICH member authority, ask about Decree 43590-S before you do anything else. It is the clearest reliance mechanism in Central America and it is routinely overlooked.

Assemble completely before filing through Regístrelo. The platform is an advantage — structured, trackable, unambiguous — but it does not reward optimism about missing documents.

Understand the CCSS before you commit. In this market the regulatory question is the easier one; the commercial question is whether you have a realistic route into a single dominant purchaser.

Consider holding the registration independently of any distributor. The professional regulatory sector here supports it, and Costa Rica is frequently a bridgehead into the wider bloc.

And if you are running a Central American programme, note that Costa Rica and Guatemala pull in different directions — Guatemala for population and public volume, Costa Rica for institutional quality and the recognition route. Most programmes want both, early.

Not legal advice. Confirm current requirements with the DRPIS and take local advice before committing funds.